Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Total Valuation
Ascendis Pharma has a market cap or net worth of $14.57B. The enterprise value is $12.98B.
Market Cap$14.57B
Enterprise Value$12.98B
Share Statistics
Ascendis Pharma has 61,977,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,977,410
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ascendis Pharma’s return on equity (ROE) is 1.35 and return on invested capital (ROIC) is -18.19%.
Return on Equity (ROE)1.35
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-18.19%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee680.15K
Profits Per Employee-215.37K
Employee Count1,017
Asset Turnover0.53
Inventory Turnover0.34
Valuation Ratios
The current PE Ratio of Ascendis Pharma is ―. Ascendis Pharma’s PEG ratio is 1.13.
PE Ratio―
PS Ratio15.90
PB Ratio-67.58
Price to Fair Value-67.58
Price to FCF252.17
Price to Operating Cash Flow248.41
PEG Ratio1.13
Income Statement
In the last 12 months, Ascendis Pharma had revenue of 691.71M and earned -219.03M in profits. Earnings per share was -3.62.
Revenue691.71M
Gross Profit588.53M
Operating Income-130.89M
Pretax Income-204.26M
Net Income-219.03M
EBITDA-113.90M
Earnings Per Share (EPS)-3.62
Cash Flow
In the last 12 months, operating cash flow was 51.17M and capital expenditures -8.39M, giving a free cash flow of 42.78M billion.
Operating Cash Flow51.17M
Free Cash Flow42.78M
Free Cash Flow per Share0.69
Dividends & Yields
Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.56
52-Week Price Change65.12%
50-Day Moving Average222.10
200-Day Moving Average198.79
Relative Strength Index (RSI)60.56
Average Volume (3m)746.57K
Important Dates
Ascendis Pharma upcoming earnings date is May 27, 2026, TBA (Confirmed).
Last Earnings DateFeb 11, 2026
Next Earnings DateMay 27, 2026
Ex-Dividend Date―
Financial Position
Ascendis Pharma as a current ratio of 1.04, with Debt / Equity ratio of -535.43%
Current Ratio1.04
Quick Ratio0.76
Debt to Market Cap0.08
Net Debt to EBITDA-2.24
Interest Coverage Ratio-1.69
Taxes
In the past 12 months, Ascendis Pharma has paid 14.78M in taxes.
Income Tax14.78M
Effective Tax Rate-0.07
Enterprise Valuation
Ascendis Pharma EV to EBITDA ratio is -98.82, with an EV/FCF ratio of 258.03.
EV to Sales16.27
EV to EBITDA-98.82
EV to Free Cash Flow258.03
EV to Operating Cash Flow217.41
Balance Sheet
Ascendis Pharma has $615.78M in cash and marketable securities with $871.41M in debt, giving a net cash position of -$255.64M billion.
Cash & Marketable Securities$615.78M
Total Debt$871.41M
Net Cash-$255.64M
Net Cash Per Share-$4.12
Tangible Book Value Per Share-$2.75
Margins
Gross margin is 86.28%, with operating margin of -18.92%, and net profit margin of -31.67%.
Gross Margin86.28%
Operating Margin-18.92%
Pretax Margin-29.53%
Net Profit Margin-31.67%
EBITDA Margin-16.47%
EBIT Margin-18.92%
Analyst Forecast
The average price target for Ascendis Pharma is $293.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$293.33
Price Target Upside21.89% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast103.32%
EPS Growth Forecast47.55%